All In Biotech

Drug Trial Radar · NCT06696768

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jun 23, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
NIH
First posted
Nov 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLFOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.

Conditions

  • Metastatic Colorectal Adenocarcinoma
  • Stage III Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Unresectable Colorectal Adenocarcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • EmavusertibBiological

    Given PO

  • FluorouracilDrug

    Given IV

  • Leucovorin CalciumDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • OxaliplatinDrug

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLT)Time frame: Up to 2 cycles (Cycle length = 14 days)
  2. Incidence of treatment-emergent adverse eventsTime frame: Up to 2 cycles (Cycle length = 14 days)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Memorial Hospital East

    Shiloh, Illinois · Recruiting

  • University of Kansas Clinical Research Center

    Fairway, Kansas · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri · Recruiting

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center-South County

    St Louis, Missouri · Recruiting

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.